Es gab 29 kürzliche Insider-Transaktionen für Alto Neuroscience, Inc. (ANRO), darunter 22 Käufe und 6 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $15.96M und die gesamten Insider-Verkäufe auf $3.27M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Etkin Amit, Smith Nicholas Conrad, Hanley Jr. Michael Conick. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — ANRO
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2026-03-01 |
Etkin Amit |
President and CEO |
RSU-Steuereinbehalt |
6,227 |
$19.69 |
$122.61K |
1,233,949 |
| 2026-03-01 |
Smith Nicholas Conrad |
Chief Financial Officer & Cbo |
RSU-Steuereinbehalt |
2,806 |
$19.69 |
$55.25K |
24,060 |
| 2026-02-11 |
Hanley Jr. Michael Conick |
Chief Operating Officer |
RSU-Zuteilung |
131,000 |
$16.71 |
$2.19M |
131,000 |
| 2026-02-11 |
Etkin Amit |
President and CEO |
RSU-Zuteilung |
306,000 |
$16.71 |
$5.11M |
306,000 |
| 2026-02-11 |
Savitz Adam |
Chief Medical Officer |
RSU-Zuteilung |
124,000 |
$16.71 |
$2.07M |
124,000 |
| 2026-02-11 |
Smith Nicholas Conrad |
Chief Financial Officer & Cbo |
RSU-Zuteilung |
200,000 |
$16.71 |
$3.34M |
200,000 |
| 2026-01-02 |
Sanchez Ramiro |
Director |
RSU-Zuteilung |
3,806 |
$16.59 |
$63.14K |
3,806 |
| 2026-01-02 |
Cox Christopher Nixon |
Director |
RSU-Zuteilung |
7,189 |
$16.59 |
$119.27K |
7,189 |
| 2026-01-02 |
York Gwill |
Director |
RSU-Zuteilung |
5,243 |
$16.59 |
$86.98K |
5,243 |
| 2026-01-02 |
Manji Husseini |
Director |
RSU-Zuteilung |
4,228 |
$16.59 |
$70.14K |
4,228 |
| 2025-08-12 |
Sanchez Ramiro |
Director |
Unbekannt |
- |
- |
- |
- |
| 2025-08-12 |
Sanchez Ramiro |
Director |
RSU-Zuteilung |
3,928 |
$3.18 |
$12.49K |
3,928 |
| 2025-07-03 |
Hanley Jr. Michael Conick |
Chief Operating Officer |
Aktienrückgabe |
8,000 |
$14.88 |
$119.04K |
- |
| 2025-07-03 |
Etkin Amit |
President and CEO |
Aktienrückgabe |
247,290 |
$5.30 |
$1.31M |
- |
| 2025-07-03 |
Savitz Adam |
Chief Medical Officer |
Aktienrückgabe |
76,000 |
$4.20 |
$319.2K |
- |
| 2025-07-03 |
Smith Nicholas Conrad |
Chief Financial Officer & Cbo |
Aktienrückgabe |
90,000 |
$14.88 |
$1.34M |
- |
| 2025-05-13 |
Dreyfus Andrew |
Director |
RSU-Zuteilung |
15,287 |
$2.37 |
$36.23K |
15,287 |
| 2025-05-13 |
Cox Christopher Nixon |
Director |
RSU-Zuteilung |
15,287 |
$2.37 |
$36.23K |
15,287 |
| 2025-05-13 |
York Gwill |
Director |
RSU-Zuteilung |
15,287 |
$2.37 |
$36.23K |
15,287 |
| 2025-05-13 |
Manji Husseini |
Director |
RSU-Zuteilung |
15,287 |
$2.37 |
$36.23K |
15,287 |
| 2025-02-05 |
Hanley Jr. Michael Conick |
Chief Operating Officer |
RSU-Zuteilung |
125,000 |
$4.20 |
$525K |
125,000 |
| 2025-02-05 |
Etkin Amit |
President and CEO |
RSU-Zuteilung |
215,000 |
$4.20 |
$903K |
215,000 |
| 2025-02-05 |
Savitz Adam |
Chief Medical Officer |
RSU-Zuteilung |
76,000 |
$4.20 |
$319.2K |
76,000 |
| 2025-02-05 |
Smith Nicholas Conrad |
Chief Financial Officer & Cbo |
RSU-Zuteilung |
135,000 |
$4.20 |
$567K |
135,000 |
| 2025-01-02 |
Cox Christopher Nixon |
Director |
RSU-Zuteilung |
25,236 |
$4.38 |
$110.53K |
25,236 |
| 2025-01-02 |
York Gwill |
Director |
RSU-Zuteilung |
19,558 |
$4.38 |
$85.66K |
19,558 |
| 2025-01-02 |
Manji Husseini |
Director |
RSU-Zuteilung |
14,195 |
$4.38 |
$62.17K |
14,195 |
| 2024-07-10 |
Savitz Adam |
Chief Medical Officer |
Informierter Kauf |
2,931 |
$13.22 |
$38.75K |
39,851 |
| 2024-07-09 |
Savitz Adam |
Chief Medical Officer |
Informierter Kauf |
10,681 |
$12.53 |
$133.83K |
35,532 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
